23andMe Halts Health-Related Genetic Test Sales

Ancestry information and raw data will still be available, as the company undergoes FDA review.

National Journal
Sophie Novack
Add to Briefcase
See more stories about...
Sophie Novack
Dec. 6, 2013, 5:31 a.m.

Dir­ect-to-con­sumer ge­net­ic test­ing com­pany 23andMe will stop sales of health-re­lated tests fol­low­ing a warn­ing let­ter from the Food and Drug Ad­min­is­tra­tion two weeks ago.

“23andMe has been giv­ing con­sumers ac­cess to health in­form­a­tion for six years and is com­mit­ted to find­ing the right reg­u­lat­ory path for our cus­tom­ers,” CEO and founder Anne Wo­j­cicki wrote in a state­ment on the com­pany web­site Thursday. “I am highly dis­ap­poin­ted that we have reached this point and will work hard to make sure con­sumers have dir­ect ac­cess to health in­form­a­tion in the near fu­ture. Our goal is to work co­oper­at­ively with the FDA to provide that op­por­tun­ity.”

The goal of 23andMe is to provide con­sumers with dir­ect ac­cess to their ge­net­ic in­form­a­tion in an easy and af­ford­able way. A test can be pur­chased on­line for $99, and provides re­ports on 254 dif­fer­ent con­di­tions and dis­eases.

However, the FDA ex­pressed con­cerns that the com­pany was selling its product as a dia­gnost­ic test for health risks. The agency said 23andMe must gain gov­ern­ment au­thor­iz­a­tion be­fore con­tinu­ing to mar­ket the product as a med­ic­al test.

The com­pany will con­tin­ue to provide an­ces­try in­form­a­tion and raw data to con­sumers, but will put the sale of health-re­lated res­ults on hold.

In­di­vidu­als who pur­chased ge­net­ic test­ing kits pri­or to when the FDA let­ter was sent on Nov. 22 will con­tin­ue to have ac­cess to their full res­ults. Those who pur­chased them on or after that date will only re­ceive an­ces­try in­form­a­tion and raw data, and will be eli­gible for a re­fund.

Wo­j­cicki em­phas­ized that the com­pany stands by their data, not­ing that the samples are sent to CLIA cer­ti­fied labs — the same stand­ards used for most health-re­lated tests.

“The in­form­a­tion 23andMe provides is in­cred­ibly ac­cur­ate,” 23andMe spokes­wo­man Cath­er­ine Afar­i­an told Na­tion­al Journ­al in early Novem­ber. “If we tell you you’re a C-C there, you are. From there, the next step is in­ter­pret­a­tion — what does sci­ence know about it?”

This is where the res­ults be­come less clear. 

As Na­tion­al Journ­al pre­vi­ously re­por­ted, there is a sig­ni­fic­ant amount of un­cer­tainty re­gard­ing the in­ter­pret­a­tion side of these test res­ults. The con­cern is that in­di­vidu­als may make im­port­ant med­ic­al de­cisions based on res­ults that are con­stantly chan­ging and that even ex­perts don’t com­pletely un­der­stand.

The com­pany will con­tin­ue to move for­ward with the FDA’s reg­u­lat­ory re­view pro­cess, and hopes to re­sume of­fer­ing health-re­lated in­form­a­tion shortly.

What We're Following See More »
FORMER GOVERNOR, AMBASSADOR TO CHINA
Jon Huntsman in Line to be #2 at State
44 minutes ago
THE DETAILS
SHOW OF UNITY
Ellison Bringing New DNC Chair Perez To Trump’s Address
49 minutes ago
BREAKING
CASE TO CARRY ON
DOJ Drops Claim Against Texas’s Voter ID Law
1 hours ago
THE LATEST

The Department of Justice "is dropping a discrimination claim against a Texas law that required voters to present identification at the polls." The case will continue to carry on with private groups who filed the lawsuit. The DOJ dropped the claim because Texas is planning to "cure the deficiencies" with the law, according to a draft copy of the dismissal motion the DOJ sent to the Campaign Legal Center. Texas Governor Jim Abbott tweeted a picture of a headline sharing the information with a caption saying "It's a new day in D.C."

Source:
TROUBLE LOOMING?
Durbin Says Government Shutdown Possible
2 hours ago
THE LATEST
AT LEAST 19 TODAY
Jewish Community Keeps Receiving Threats
2 hours ago
THE DETAILS
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login